President Donald Trump signed an executive order on Saturday directing federal agencies to expedite research on psychedelics like LSD and ibogaine, which are currently illegal but show promise in treating conditions such as PTSD, depression, and addiction. The order was flanked by Health and Human Services Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and other health officials.
Core Facts and Immediate Action
- Executive Order Signed: Trump directed the FDA to prioritize research on psychedelics, including ibogaine, under the Right to Try Act, allowing terminally ill patients access to unapproved treatments.
- $50 Million Investment: The federal government committed $50 million to research ibogaine, with the FDA adding three psychedelics to the National Priority Voucher program to speed up reviews.
Deeper Dive & Context
Key Participants and Motivations
- Joe Rogan's Role: Rogan, a Trump endorser in 2024, reportedly influenced the order by sharing data on ibogaine’s efficacy in treating addiction. Trump joked about Rogan’s more liberal stance but praised his advocacy.
- Veteran Focus: Trump emphasized the order’s potential to address veteran suicide rates, citing PTSD as a critical unmet need.
Policy and Procedural Changes
- Right to Try Act: The order allows terminally ill patients to access psychedelics before full FDA approval, aligning with the act’s intent to expedite experimental treatments.
- National Priority Vouchers: The FDA will fast-track psychedelics deemed high-priority, reducing review times for drugs targeting national health priorities.
Opposing Views and Implications
- Proponents’ Perspective: Supporters, including Kennedy and veterans who have used ibogaine, argue the order could revolutionize mental health treatment.
- Skeptical Voices: While not explicitly stated in the sources, critics may question the rapid pace of the order’s drafting and potential risks of unregulated psychedelic use.
Long-Term Implications
- Research Expansion: The order could lead to broader clinical trials and eventual FDA approval for psychedelics, potentially reshaping mental health treatment.
- Political and Public Health Impact: The move may influence future policy debates on drug legalization and access to experimental therapies.